Analysis of AstraZeneca Pharma India receives CDSCO approval for trastuzumab deruxtecan followed by taxane, trastuzumab, and pertuzumab (THP) for adults with HER2-positive Stage II or III early breast cancer - aVenture Research
astrazeneca.in
AstraZeneca Pharma India receives CDSCO approval for trastuzumab deruxtecan followed by taxane, trastuzumab, and pertuzumab (THP) for adults with HER2-positive Stage II or III early breast cancer
Bangalore, 28 July 2026: AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for trastuzumab deruxtecan 100 mg/5 mL vial lyophilised powder for concentrate for solution for infusion. The approval is for trastuzumab deruxtecan followed by a taxane, trastuzumab, and pertuzumab (THP) indicated for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer